A Phase 1 interventional study of anti-Abeta and placebo in Alzheimer's Disease, sponsored by Genentech, Inc.. Completed. Open to participants aged 50 Years to 86 Years. Per ClinicalTrials.gov, last updated 2010-10-27.
Sponsored by Genentech, Inc. · Phase 1, Interventional, and Treatment
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study that will be conducted in the United States and consists of a single ascending-dose stage followed by a multidose, parallel-treatment stage. This study will be conducted in approximately 50 adult patients between 50-85 years old who have mild to moderate Alzheimer's disease.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's enrollment of 56 is below the median of 70 across 2,808 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Genentech, Inc. is the lead sponsor of 507 studies on the registry; 23 are open to participants now.
Of its 90 completed or terminated interventional studies of FDA-regulated products, 50 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intravenous single and multiple doses
Intravenous single and multiple doses
Safety and tolerability of single and multiple doses of MABT5102A
Time frame: Through study completion or early study discontinuation
Pharmacokinetics of MABT5102A after single and multiple doses
Time frame: Through study completion or early study discontinuation
Immunogenicity of MABT5102A after single and multiple doses
Time frame: Through study completion or early study discontinuation
No study locations are listed for this record.
This study is completed, as verified in Oct 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genentech, Inc.